Harvard Bioscience Inc.
HBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.22M
Close$
$-3.22
140.1% downside
Current Fair Value
140.1% downsideOvervalued by 140.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.22 Million |
|---|---|
| Enterprise Value | $77.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.8 |
| Beta | 1.53 |
| Outstanding Shares | 4,526,000 |
Return
| Return on Equity | -140.36% |
|---|---|
| Return on Assets | -13.65% |
| Return on Invested Capital | 97.04% |
Valuation & Multiples
| P/E Ratio | -3.45 |
|---|---|
| PEG | -12.54 |
| Price to Sales | 0.42 |
| Price to Book Ratio | 8.03 |
| Enterprise Value to Revenue | 0.88 |
| Enterprise Value to EBIT | 1.55 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | 6.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$21.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$21.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 29.90%▼ 5.55% |
|---|---|
| Total Invested | $8.32M▲ 7.72% |
| Investors Holding | 34▼ 2.00% |
ESG Score
No data